Management of perihilar cholangiocarcinoma in the era of multimodal therapy

References

• Altemeier WA, Gall EA, Zinninger MM, Hoxworth PI. Sclerosing carcinoma of the major intrahepatic bile ducts. AMA. Arch. Surg. 75(3), 450–60; discussion 460 (1957).
   PubMedGoogle Scholar
• Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. an unusual tumor with distinctive clinical and pathological features. Am. J. Med. 38, 241–256 (1965).
   PubMed Web of Science ®Google Scholar
• Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann. Surg. 250(2), 210–218 (2009).
   PubMedGoogle Scholar
• Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann. Surg. 228(3), 385–394 (1998).
   PubMed Web of Science ®Google Scholar
• DeOliveira ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245(5), 755–762 (2007).
   PubMed Web of Science ®Google Scholar
• Nakeeb A, Pitt HA, Sohn TA et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 224(4), 463–473; discussion 473 (1996).
   PubMed Web of Science ®Google Scholar
• Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J. Hepatol. 40(3), 472–477 (2004).
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol. Biomarkers Prev. 15(6), 1198–1203 (2006).
   PubMed Web of Science ®Google Scholar
• Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R; AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig. Liver Dis. 42(7), 490–495 (2010).
   PubMedGoogle Scholar
• Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin. Liver Dis. 24(2), 115–125 (2004).
   PubMed Web of Science ®Google Scholar
• Khan SA, Emadossadaty S, Ladep NG et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J. Hepatol. 56(4), 848–854 (2011).
   PubMedGoogle Scholar
• Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J. Natl Cancer Inst. 98(12), 873–875 (2006).
   PubMedGoogle Scholar
• Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2, 10 (2002).
   PubMed Web of Science ®Google Scholar
• Welzel TM, Graubard BI, El-Serag HB et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case–control study. Clin. Gastroenterol. Hepatol. 5(10), 1221–1228 (2007).
   PubMed Web of Science ®Google Scholar
• Choi D, Lim JH, Lee KT et al. Cholangiocarcinoma and Clonorchis sinensis infection: a case–control study in Korea. J. Hepatol. 44(6), 1066–1073 (2006).
   PubMedGoogle Scholar
• Parkin DM, Srivatanakul P, Khlat M et al. Liver cancer in Thailand. I. A case–control study of cholangiocarcinoma. Int. J. Cancer 48(3), 323–328 (1991).
   PubMed Web of Science ®Google Scholar
• Chalasani N, Baluyut A, Ismail A et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case–control study. Hepatology 31(1), 7–11 (2000).
   PubMed Web of Science ®Google Scholar
• Bergquist A, Glaumann H, Persson B, Broomé U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case–control study. Hepatology 27(2), 311–316 (1998).
   PubMed Web of Science ®Google Scholar
• Broomé U, Olsson R, Lööf L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38(4), 610–615 (1996).
   PubMed Web of Science ®Google Scholar
• Aadland E, Schrumpf E, Fausa O et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22(6), 655–664 (1987).
   PubMed Web of Science ®Google Scholar
• Nordenstedt H, Mattsson F, El-Serag H, Lagergren J. Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma. Br. J. Cancer 106(5), 1011–1015 (2012).
   PubMed Web of Science ®Google Scholar
• Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL. Choledochal cyst disease. A changing pattern of presentation. Ann. Surg. 220(5), 644–652 (1994).
   PubMedGoogle Scholar
• Chijiiwa K, Koga A. Surgical management and long-term follow-up of patients with choledochal cysts. Am. J. Surg. 165(2), 238–242 (1993).
   PubMed Web of Science ®Google Scholar
• Choi BI, Han JK, Hong ST, Lee KH. Clonorchiasis and cholangiocarcinoma: etiologic relationship and imaging diagnosis. Clin. Microbiol. Rev. 17(3), 540–552 (2004).
   PubMed Web of Science ®Google Scholar
• Hong ST, Kho WG, Kim WH, Chai JY, Lee SH. Turnover of biliary epithelial cells in Clonorchis sinensis infected rats. Korean J. Parasitol. 31(2), 83–89 (1993).
   PubMedGoogle Scholar
• Watanapa P. Cholangiocarcinoma in patients with opisthorchiasis. Br. J. Surg. 83(8), 1062–1064 (1996).
   PubMedGoogle Scholar
• Wetter LA, Ring EJ, Pellegrini CA, Way LW. Differential diagnosis of sclerosing cholangiocarcinomas of the common hepatic duct (Klatskin tumors). Am. J. Surg. 161(1), 57–62; discussion 62 (1991).
   PubMedGoogle Scholar
• Verbeek PC, van Leeuwen DJ, de Wit LT et al. Benign fibrosing disease at the hepatic confluence mimicking Klatskin tumors. Surgery 112(5), 866–871 (1992).
   PubMedGoogle Scholar
• Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 95(1), 204–207 (2000).
   PubMed Web of Science ®Google Scholar
• Juntermanns B, Radunz S, Heuer M et al. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur. J. Med. Res. 15(8), 357–361 (2010).
   PubMed Web of Science ®Google Scholar
• Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin. Gastroenterol. Hepatol. 9(5), 434–439.e1 (2011).
   PubMed Web of Science ®Google Scholar
• Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108(3), 865–869 (1995).
   PubMed Web of Science ®Google Scholar
• Gakhal MS, Gheyi VK, Brock RE, Andrews GS. Multimodality imaging of biliary malignancies. Surg. Oncol. Clin. N. Am. 18(2), 225–239, vii (2009).
   PubMedGoogle Scholar
• Unno M, Okumoto T, Katayose Y et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J. Hepatobiliary. Pancreat. Surg. 14(5), 434–440 (2007).
   PubMedGoogle Scholar
• Chen HW, Lai EC, Pan AZ, Chen T, Liao S, Lau WY. Preoperative assessment and staging of hilar cholangiocarcinoma with 16-multidetector computed tomography cholangiography and angiography. Hepatogastroenterology 56(91–92), 578–583 (2009).
   PubMedGoogle Scholar
• Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J. Hepatol. 45(6), 856–867 (2006).
   PubMed Web of Science ®Google Scholar
• Rösch T, Meining A, Frühmorgen S et al. A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest. Endosc. 55(7), 870–876 (2002).
   PubMed Web of Science ®Google Scholar
• Reinhold C, Bret PM. Current status of MR cholangiopancreatography. AJR. Am. J. Roentgenol. 166(6), 1285–1295 (1996).
   PubMed Web of Science ®Google Scholar
• Zidi SH, Prat F, Le Guen O, Rondeau Y, Pelletier G. Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures. Gut 46(1), 103–106 (2000).
   PubMed Web of Science ®Google Scholar
• Sai JK, Suyama M, Kubokawa Y, Watanabe S, Maehara T. Early detection of extrahepatic bile-duct carcinomas in the nonicteric stage by using MRCP followed by EUS. Gastrointest. Endosc. 70(1), 29–36 (2009).
   PubMed Web of Science ®Google Scholar
• Cho ES, Park MS, Yu JS, Kim MJ, Kim KW. Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography. J. Comput. Assist. Tomogr. 31(1), 72–78 (2007).
   PubMed Web of Science ®Google Scholar
• Cui XY, Chen HW. Role of diffusion-weighted magnetic resonance imaging in the diagnosis of extrahepatic cholangiocarcinoma. World J. Gastroenterol. 16(25), 3196–3201 (2010).
   PubMed Web of Science ®Google Scholar
• Keiding S, Hansen SB, Rasmussen HH et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 28(3), 700–706 (1998).
   PubMedGoogle Scholar
• Prytz H, Keiding S, Björnsson E et al.; Swedish Internal Medicine Liver Club. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 44(6), 1572–1580 (2006).
   PubMed Web of Science ®Google Scholar
• Petrowsky H, Wildbrett P, Husarik DB et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J. Hepatol. 45(1), 43–50 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J. Gastrointest. Surg. 8(1), 90–97 (2004).
   PubMedGoogle Scholar
• Park MS, Kim TK, Kim KW et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology 233(1), 234–240 (2004).
   PubMed Web of Science ®Google Scholar
• Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur. J. Surg. Oncol. 31(5), 533–539 (2005).
   PubMedGoogle Scholar
• Ponchon T, Gagnon P, Berger F et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest. Endosc. 42(6), 565–572 (1995).
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Atomi Y, Wada N, Kuroda A, Muto T. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am. J. Gastroenterol. 91(3), 465–467 (1996).
   PubMed Web of Science ®Google Scholar
• Kubota Y, Takaoka M, Tani K et al. Endoscopic transpapillary biopsy for diagnosis of patients with pancreaticobiliary ductal strictures. Am. J. Gastroenterol. 88(10), 1700–1704 (1993).
   PubMedGoogle Scholar
• Tamada K, Tomiyama T, Wada S et al. Endoscopic transpapillary bile duct biopsy with the combination of intraductal ultrasonography in the diagnosis of biliary strictures. Gut 50(3), 326–331 (2002).
   PubMedGoogle Scholar
• Tamada K, Satoh Y, Tomiyama T et al. Multiple bile duct biopsies using a sheath with a side port: usefulness of intraductal sonography. AJR. Am. J. Roentgenol. 176(3), 797–802 (2001).
   PubMedGoogle Scholar
• Ferrero A, Lo Tesoriere R, Viganò L, Caggiano L, Sgotto E, Capussotti L. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J. Surg. 33(2), 318–325 (2009).
   PubMedGoogle Scholar
• Chen YK, Pleskow DK. SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest. Endosc. 65(6), 832–841 (2007).
   PubMed Web of Science ®Google Scholar
• Fukuda Y, Tsuyuguchi T, Sakai Y, Tsuchiya S, Saisyo H. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. Gastrointest. Endosc. 62(3), 374–382 (2005).
   PubMed Web of Science ®Google Scholar
• Fishman DS, Tarnasky PR, Patel SN, Raijman I. Management of pancreaticobiliary disease using a new intra-ductal endoscope: the Texas experience. World J. Gastroenterol. 15(11), 1353–1358 (2009).
   PubMedGoogle Scholar
• Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg. Gynecol. Obstet. 140(2), 170–178 (1975).
   PubMedGoogle Scholar
• Jarnagin WR, Fong Y, DeMatteo RP et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 234(4), 507–17; discussion 517 (2001).
   PubMed Web of Science ®Google Scholar
• Chen RF, Li ZH, Zhou JJ et al. Preoperative evaluation with T-staging system for hilar cholangiocarcinoma. World J. Gastroenterol. 13(43), 5754–5759 (2007).
   PubMedGoogle Scholar
• American Joint Committee on Cancer. Cancer Staging Manual. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). Springer, NY, USA (2010).
   Google Scholar
• de Jong MC, Hong SM, Augustine MM et al. Hilar cholangiocarcinoma: tumor depth as a predictor of outcome. Arch. Surg. 146(6), 697–703 (2011).
   PubMedGoogle Scholar
• Deoliveira ML, Schulick RD, Nimura Y et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53(4), 1363–1371 (2011).
   PubMed Web of Science ®Google Scholar
• Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch. Surg. 137(6), 675–680; discussion 680 (2002).
   PubMedGoogle Scholar
• Melendez J, Ferri E, Zwillman M et al. Extended hepatic resection: a 6-year retrospective study of risk factors for perioperative mortality. J. Am. Coll. Surg. 192(1), 47–53 (2001).
   PubMedGoogle Scholar
• Vauthey JN, Baer HU, Guastella T, Blumgart LH. Comparison of outcome between extended and nonextended liver resections for neoplasms. Surgery 114(5), 968–975 (1993).
   PubMed Web of Science ®Google Scholar
• Tsao JI, Loftus JP, Nagorney DM, Adson MA, Ilstrup DM. Trends in morbidity and mortality of hepatic resection for malignancy. A matched comparative analysis. Ann. Surg. 220(2), 199–205 (1994).
   PubMed Web of Science ®Google Scholar
• Makuuchi M, Thai BL, Takayasu K et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107(5), 521–527 (1990).
   PubMed Web of Science ®Google Scholar
• Hemming AW, Reed AI, Howard RJ et al. Preoperative portal vein embolization for extended hepatectomy. Ann. Surg. 237(5), 686–691; discussion 691 (2003).
   PubMed Web of Science ®Google Scholar
• Madoff DC, Hicks ME, Vauthey JN et al. Transhepatic portal vein embolization: anatomy, indications, and technical considerations. Radiographics 22(5), 1063–1076 (2002).
   PubMed Web of Science ®Google Scholar
• Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br. J. Surg. 88(2), 165–175 (2001).
   PubMed Web of Science ®Google Scholar
• Nagino M, Nimura Y, Kamiya J et al. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology 21(2), 434–439 (1995).
   PubMed Web of Science ®Google Scholar
• Launois B, Reding R, Lebeau G, Buard JL. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J. Hepatobiliary. Pancreat. Surg. 7(2), 128–134 (2000).
   PubMedGoogle Scholar
• Seyama Y, Kubota K, Sano K et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann. Surg. 238(1), 73–83 (2003).
   PubMedGoogle Scholar
• Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J. Clin. Oncol. 15(3), 947–954 (1997).
   PubMedGoogle Scholar
• Nimura Y, Kamiya J, Kondo S et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J. Hepatobiliary. Pancreat. Surg. 7(2), 155–162 (2000).
   PubMedGoogle Scholar
• Todoroki T, Kawamoto T, Koike N et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br. J. Surg. 87(3), 306–313 (2000).
   PubMed Web of Science ®Google Scholar
• Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, van Gulik TM. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann. Surg. Oncol. 13(6), 872–880 (2006).
   PubMedGoogle Scholar
• Gerhards MF, van Gulik TM, de Wit LT, Obertop H, Gouma DJ. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma–a single center experience. Surgery 127(4), 395–404 (2000).
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Bowne W, Klimstra DS et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann. Surg. 241(5), 703–712; discussion 712 (2005).
   PubMed Web of Science ®Google Scholar
• Neuhaus P, Jonas S, Bechstein WO et al. Extended resections for hilar cholangiocarcinoma. Ann. Surg. 230(6), 808–818; discussion 819 (1999).
   PubMed Web of Science ®Google Scholar
• Ito F, Agni R, Rettammel RJ et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann. Surg. 248(2), 273–279 (2008).
   PubMedGoogle Scholar
• Lillemoe KD, Cameron JL. Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach. J. Hepatobiliary. Pancreat. Surg. 7(2), 115–121 (2000).
   PubMedGoogle Scholar
• Kawasaki S, Imamura H, Kobayashi A, Noike T, Miwa S, Miyagawa S. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann. Surg. 238(1), 84–92 (2003).
   PubMed Web of Science ®Google Scholar
• Kondo S, Hirano S, Ambo Y et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann. Surg. 240(1), 95–101 (2004).
   PubMed Web of Science ®Google Scholar
• Nimura Y, Hayakawa N, Kamiya J, Kondo S, Shionoya S. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J. Surg. 14(4), 535–543; discussion 544 (1990).
   PubMedGoogle Scholar
• Cannon RM, Brock G, Buell JF. Surgical resection for hilar cholangiocarcinoma: experience improves resectability. HPB (Oxford) 14(2), 142–149 (2012).
   PubMedGoogle Scholar
• Rea DJ, Munoz-Juarez M, Farnell MB et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch. Surg. 139(5), 514–523; discussion 523 (2004).
   PubMedGoogle Scholar
• Gazzaniga GM, Filauro M, Bagarolo C, Mori L. Surgery for hilar cholangiocarcinoma: an Italian experience. J. Hepatobiliary. Pancreat. Surg. 7(2), 122–127 (2000).
   PubMedGoogle Scholar
• Kow AW, Wook CD, Song SC et al. Role of caudate lobectomy in type III a and III b hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J. Surg. 36(5), 1112–1121 (2012).
   PubMedGoogle Scholar
• Kitagawa Y, Nagino M, Kamiya J et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann. Surg. 233(3), 385–392 (2001).
   PubMed Web of Science ®Google Scholar
• Muñoz L, Roayaie S, Maman D et al. Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. J. Hepatobiliary. Pancreat. Surg. 9(2), 237–241 (2002).
   PubMedGoogle Scholar
• Hemming AW, Kim RD, Mekeel KL et al. Portal vein resection for hilar cholangiocarcinoma. Am. Surg. 72(7), 599–604; discussion 604 (2006).
   PubMedGoogle Scholar
• Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann. Surg. 238(5), 720–727 (2003).
   PubMedGoogle Scholar
• Nuzzo G, Giuliante F, Ardito F et al.; Italian Chapter of the International Hepato-Pancreato-Biliary Association. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch. Surg. 147(1), 26–34 (2012).
   PubMedGoogle Scholar
• Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J. Surg. 31(6), 1256–1263 (2007).
   PubMedGoogle Scholar
• Park SW, Park YS, Chung JB et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology 51(60), 1612–1618 (2004).
   PubMedGoogle Scholar
• Schiffman SC, Reuter NP, Mcmasters KM, Scoggins CR, Martin RC. Overall survival peri-hilar cholangiocarcinoma: R1 resection with curative intent compared to primary endoscopic therapy. J. Surg. Oncol. 105(1), 91–96 (2011).
   PubMedGoogle Scholar
• Rao S, Cunningham D, Hawkins RE et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br. J. Cancer 92(9), 1650–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br. J. Cancer 96(6), 896–902 (2007).
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH et al.; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Murakami Y, Uemura K, Sudo T et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J. Gastrointest. Surg. 13(8), 1470–1479 (2009).
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Schueller J, Heubrandtner U et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a Phase 2 study. Lancet Oncol. 11(12), 1142–1148 (2010).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Meyerhardt JA, Blaszkowsky LS et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a Phase 2 study. Lancet Oncol. 11(1), 48–54 (2010).
   PubMed Web of Science ®Google Scholar
• Bengala C, Bertolini F, Malavasi N et al. Sorafenib in patients with advanced biliary tract carcinoma: a Phase II trial. Br. J. Cancer 102(1), 68–72 (2010).
   PubMed Web of Science ®Google Scholar
• Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am. J. Surg. 159(1), 91–97; discussion 97 (1990).
   PubMed Web of Science ®Google Scholar
• Pitt HA, Nakeeb A, Abrams RA et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann. Surg. 221(6), 788–797; discussion 797 (1995).
   PubMed Web of Science ®Google Scholar
• Zlotecki RA, Jung LA, Vauthey JN, Vogel SB, Mendenhall WM. Carcinoma of the extrahepatic biliary tract: surgery and radiotherapy for curative and palliative intent. Radiat. Oncol. Investig. 6(5), 240–247 (1998).
   PubMedGoogle Scholar
• Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg. Today 35(7), 548–552 (2005).
   PubMed Web of Science ®Google Scholar
• Todoroki T, Ohara K, Kawamoto T et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 46(3), 581–587 (2000).
   PubMed Web of Science ®Google Scholar
• Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur. J. Surg. Oncol. 33(2), 202–207 (2007).
   PubMed Web of Science ®Google Scholar
• Gerhards MF, van Gulik TM, González González D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J. Surg. 27(2), 173–179 (2003).
   PubMed Web of Science ®Google Scholar
• Stein DE, Heron DE, Rosato EL, Anné PR, Topham AK. Positive microscopic margins alter outcome in lymph ­node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am. J. Clin. Oncol. 28(1), 21–23 (2005).
   PubMedGoogle Scholar
• Ohnishi H, Asada M, Shichijo Y et al. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology. 42(3), 265–268 (1995).
   PubMed Web of Science ®Google Scholar
• Kuvshinoff BW, Armstrong JG, Fong Y et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br. J. Surg. 82(11), 1522–1525 (1995).
   PubMed Web of Science ®Google Scholar
• Minn AY, Koong AC, Chang DT. Stereotactic body radiation therapy for gastrointestinal malignancies. Front. Radiat. Ther. Oncol. 43, 412–427 (2011).
   PubMedGoogle Scholar
• Momm F, Schubert E, Henne K et al. Stereotactic fractionated radiotherapy for Klatskin tumours. Radiother. Oncol. 95(1), 99–102 (2010).
   PubMed Web of Science ®Google Scholar
• Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 39(6), 852–855 (1996).
   PubMedGoogle Scholar
• Fingar VH, Wieman TJ. Studies on the mechanism of photodynamic therapy induced tumor destruction. Proc. SPIE 1203, 168–177 (1990).
   Google Scholar
• Wong Kee Song LM, Wang KK, Zinsmeister AR. Mono-l-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 82(2), 421–427 (1998).
   PubMedGoogle Scholar
• Cunningham SC, Choti MA, Bellavance EC, Pawlik TM. Palliation of hepatic tumors. Surg. Oncol. 16(4), 277–291 (2007).
   PubMed Web of Science ®Google Scholar
• Berr F, Wiedmann M, Tannapfel A et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 31(2), 291–298 (2000).
   PubMedGoogle Scholar
• Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am. J. Gastroenterol. 100(11), 2426–2430 (2005).
   PubMed Web of Science ®Google Scholar
• Ortner ME, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125(5), 1355–1363 (2003).
   PubMed Web of Science ®Google Scholar
• Cheon YK, Lee TY, Lee SM, Yoon JY, Shim CS. Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma. HPB (Oxford). 14(3), 185–193 (2012).
   PubMed Web of Science ®Google Scholar
• Wiedmann M, Caca K, Berr F et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a Phase II pilot study. Cancer 97(11), 2783–2790 (2003).
   PubMed Web of Science ®Google Scholar
• Petersen BT, Chuttani R, Croffie J et al. Photodynamic therapy for gastrointestinal disease. Gastrointest. Endosc. 63(7), 927–932 (2006).
   PubMedGoogle Scholar
• Iwatsuki S, Todo S, Marsh JW et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J. Am. Coll. Surg. 187(4), 358–364 (1998).
   PubMed Web of Science ®Google Scholar
• Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69(8), 1633–1637 (2000).
   PubMed Web of Science ®Google Scholar
• Shimoda M, Farmer DG, Colquhoun SD et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 7(12), 1023–1033 (2001).
   PubMed Web of Science ®Google Scholar
• Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl. Int. 23(7), 692–697 (2010).
   PubMed Web of Science ®Google Scholar
• Murad SD, Ray Kim W, Therneau T et al. Predictors of pre-transplant dropout and post-transplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology doi:10.1002/hep.25629 (2012) (Epub ahead of print).
   Google Scholar
• Hong JC, Jones CM, Duffy JP et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch. Surg. 146(6), 683–689 (2011).
   PubMedGoogle Scholar
• Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg. 242(3), 451–458; discussion 458 (2005).
   PubMed Web of Science ®Google Scholar
• Patel T. Cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 3(1), 33–42 (2006).
   PubMedGoogle Scholar